Morgan Stanley Lowers Bausch Health Companies (NYSE:BHC) Price Target to $32.00

Share on StockTwits

Bausch Health Companies (NYSE:BHC) had its price objective reduced by Morgan Stanley from $34.00 to $32.00 in a research report released on Tuesday, BenzingaRatingsTable reports. They currently have an overweight rating on the stock.

A number of other equities analysts have also commented on the company. HC Wainwright reiterated a buy rating and issued a $60.00 price objective on shares of Bausch Health Companies in a research note on Monday, December 23rd. Goldman Sachs Group started coverage on Bausch Health Companies in a research note on Monday, December 2nd. They issued a neutral rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. upgraded Bausch Health Companies from a neutral rating to an overweight rating and lifted their price objective for the stock from $32.00 to $38.00 in a research note on Thursday, December 12th. Barclays reiterated a buy rating and issued a $33.00 price objective on shares of Bausch Health Companies in a research note on Sunday, January 26th. Finally, Wolfe Research downgraded Bausch Health Companies from an outperform rating to a peer perform rating in a research report on Wednesday, January 29th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $34.06.

Bausch Health Companies stock opened at $27.74 on Tuesday. The company has a debt-to-equity ratio of 9.17, a quick ratio of 0.86 and a current ratio of 1.15. The business’s 50-day simple moving average is $28.82 and its 200-day simple moving average is $25.51. The firm has a market capitalization of $9.67 billion, a PE ratio of 6.38, a PEG ratio of 0.57 and a beta of 1.02. Bausch Health Companies has a 52 week low of $18.72 and a 52 week high of $31.97.

A number of hedge funds have recently added to or reduced their stakes in BHC. Renaissance Technologies LLC boosted its holdings in Bausch Health Companies by 146.8% during the fourth quarter. Renaissance Technologies LLC now owns 12,491,799 shares of the company’s stock valued at $373,769,000 after purchasing an additional 7,429,396 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in Bausch Health Companies by 4.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 2,379,185 shares of the company’s stock valued at $71,185,000 after purchasing an additional 96,210 shares in the last quarter. Ardevora Asset Management LLP boosted its holdings in Bausch Health Companies by 7.1% during the third quarter. Ardevora Asset Management LLP now owns 1,916,320 shares of the company’s stock valued at $41,872,000 after purchasing an additional 127,800 shares in the last quarter. FMR LLC boosted its holdings in Bausch Health Companies by 410.9% during the fourth quarter. FMR LLC now owns 1,909,946 shares of the company’s stock valued at $57,171,000 after purchasing an additional 1,536,120 shares in the last quarter. Finally, CIBC World Markets Inc. boosted its holdings in Bausch Health Companies by 1.7% during the fourth quarter. CIBC World Markets Inc. now owns 1,906,462 shares of the company’s stock valued at $57,041,000 after purchasing an additional 32,386 shares in the last quarter. 57.38% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Recommended Story: How to Invest in an Index Fund

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

ConocoPhillips  Receives New Coverage from Analysts at Capital One Financial
ConocoPhillips Receives New Coverage from Analysts at Capital One Financial
First Trust Advisors LP Sells 44,114 Shares of H & R Block Inc
First Trust Advisors LP Sells 44,114 Shares of H & R Block Inc
CoreSite Realty  Downgraded by Bank of America
CoreSite Realty Downgraded by Bank of America
Regeneron Pharmaceuticals  Lifted to Buy at Argus
Regeneron Pharmaceuticals Lifted to Buy at Argus
First Trust Advisors LP Has $11.05 Million Stock Holdings in Alliance Data Systems Co.
First Trust Advisors LP Has $11.05 Million Stock Holdings in Alliance Data Systems Co.
QAD  Upgraded by Zacks Investment Research to Buy
QAD Upgraded by Zacks Investment Research to Buy


 
© 2006-2020 Zolmax.